Visual Acuity Outcomes in Patients Receiving Frequent Treatment of Neovascular Age-Related Macular Degeneration in Clinical Practice.

Moshfeghi, Andrew A; Pitcher, John D; Lucas, Genevieve; Boucher, Nick; Saroj, Namrata

Moshfeghi, Andrew A; Pitcher, John D; Lucas, Genevieve; Boucher, Nick; Saroj, Namrata.

Afiliação

Moshfeghi AA; Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, USA.
Pitcher JD; Eye Associates of New Mexico, Albuquerque, NM, USA.
Lucas G; Department of Ophthalmology, University of New Mexico, Albuquerque, NM, USA.
Boucher N; Vestrum Health, Ottawa, Ontario, Canada.
Saroj N; Vestrum Health, Ottawa, Ontario, Canada.

J Vitreoretin Dis ; 5(3): 221-226, 2021.

Article em En | MEDLINE | ID: mdl-37006507

Palavras-chave

antivascular endothelial growth factor; bevacizumab; intravitreal aflibercept; neovascular age-related macular degeneration; ranibizumab; real-world outcomes; treatment frequency; visual acuity

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Vitreoretin Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google